Intrinsic superoxide dismutase activity of MnO nanoparticles enhances the magnetic resonance imaging contrast

Superoxide radicals are associated with the development of many severe diseases, such as cancer. Under nonpathogenic conditions, the natural enzyme superoxide dismutase (SOD) regulates the intracellular superoxide concentrations, but nearly all tumor tissues show reduced SOD levels. Selective imagin...

Full description

Saved in:
Bibliographic Details
Published in:Journal of materials chemistry. B, Materials for biology and medicine Materials for biology and medicine, 2016-01, Vol.4 (46), p.7423-7428
Main Authors: Ragg, R, Schilmann, A M, Korschelt, K, Wieseotte, C, Kluenker, M, Viel, M, Völker, L, Preiß, S, Herzberger, J, Frey, H, Heinze, K, Blümler, P, Tahir, M N, Natalio, F, Tremel, W
Format: Article
Language:English
Subjects:
Cancer
Contrast agents
Imaging
Magnetic resonance imaging
Materials selection
Nanoparticles
Radicals
Sod
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Superoxide radicals are associated with the development of many severe diseases, such as cancer. Under nonpathogenic conditions, the natural enzyme superoxide dismutase (SOD) regulates the intracellular superoxide concentrations, but nearly all tumor tissues show reduced SOD levels. Selective imaging in early progression stages remains a key requirement for efficient cancer diagnosis and treatment. Magnetic resonance imaging (MRI) as a noninvasive tool with high spatial resolution may offer advantages here, but MRI contrast agents exhibiting a redox-triggered change in the image contrast towards superoxide radicals have not been reported so far. Here we show that manganese oxide (MnO) nanoparticles (NPs) exhibit an intrinsic SOD-like activity, which is higher than that of the native Mn-dependent SOD. In addition, MnO NPs significantly enhance the MRI contrast when exposed to superoxide radicals, making them responsive MRI contrast agents for the treatment and imaging of cancer cells with reduced SOD levels.
ISSN:2050-750X
2050-7518
DOI:10.1039/c6tb02078j